News
Publications

Thursday, February 23, 2017

Circulation Research, a Journal of the American Heart Association

Results from CardioCell’s pre-clinical studies are featured in a peer-reviewed article now available in the American Heart Association’s journal Circulation Research. Entitled “Intravenously-Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy,” the paper authors include CardioCell’s Scientific Advisory Board member Dr. Stephen E. Epstein, as well as board directors Sergey…
Read Entire Article

Monday, January 23, 2017

Circulation Research, a Journal of the American Heart Association

Dr. Jay H. Traverse, MD, FACC, FAHA, cited CardioCell’s Phase IIa chronic heart failure clinical trial results in an editorial in the January issue of the American Heart Association’s journal Circulation Research. His editorial “Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy?” examines the potential benefits of intravenous delivered allogeneic stem cell therapy. Dr. Traverse is…
Read Entire Article

Wednesday, November 16, 2016

Circulation Research, a Journal of the American Heart Association

Results from CardioCell’s Phase IIa chronic heart failure clinical trial are featured in a peer-reviewed article now available in the American Heart Association’s journal Circulation Research. Entitled “Intravenous Allogeneic Mesenchymal Stem Cells for Non-Ischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial,” the paper authors include CardioCell’s Scientific Advisory Board members Drs. Stephen E. Epstein, Arshed…
Read Entire Article

Friday, May 13, 2016

Circulation: Heart Failure, a Journal of the American Heart Association

  A major unmet need in the field of HF drug development is the ability to identify homogeneous subsets of patients whose underlying disease is driven by a specific mechanism that can be targeted using a new therapeutic agent. To understand better and address the array of challenges facing current HF drug development so that future efforts have a…
Read Entire Article

Tuesday, November 3, 2015

Journal of the American College of Cardiology

CardioCell’s Phase IIa chronic heart failure clinical trial is referenced in a peer-reviewed article now available in the Journal of the American College of Cardiology. The paper illustrates the importance the field ascribes to a stem cell strategy to treat either ischemic or non-ischemic cardiomyopathy. Entitled “Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible…
Read Entire Article

Wednesday, October 21, 2015

Journal of Cardiovascular Medicine

Details from CardioCell’s Phase IIa chronic heart failure clinical trial are featured in a peer-reviewed article now available in the Journal of Cardiovascular Medicine. Entitled “Rational and Design of a Randomized Controlled Trial of Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy,” the paper authors include CardioCell’s Scientific Advisory Board members Drs. Stephen E. Epstein, Arshed…
Read Entire Article